

Kate Cuschieri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3642769/publications.pdf>

Version: 2024-02-01

70
papers

2,076
citations

304368

22
h-index

253896

43
g-index

70
all docs

70
docs citations

70
times ranked

2497
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of infection in miscarriage. <i>Human Reproduction Update</i> , 2016, 22, 116-133.	5.2	278
2	Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. <i>Lancet Infectious Diseases</i> , 2017, 17, 1293-1302.	4.6	186
3	Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. <i>BMJ: British Medical Journal</i> , 2019, 365, l1161.	2.4	134
4	Eurogin roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programs. <i>International Journal of Cancer</i> , 2018, 143, 735-745.	2.3	124
5	VALGENT: A protocol for clinical validation of human papillomavirus assays. <i>Journal of Clinical Virology</i> , 2016, 76, S14-S21.	1.6	123
6	2020 list of human papillomavirus assays suitable for primary cervical cancer screening. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1083-1095.	2.8	116
7	Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013. <i>Emerging Infectious Diseases</i> , 2016, 22, 56-64.	2.0	98
8	Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway PaVDaG study). <i>BMJ Open</i> , 2016, 6, e010660.	0.8	64
9	Methylation markers FAM19A4 and miR124 as triage strategy for primary human papillomavirus screen positive women: A large European multicenter study. <i>International Journal of Cancer</i> , 2021, 148, 396-405.	2.3	56
10	HPV status and favourable outcome in vulvar squamous cancer. <i>International Journal of Cancer</i> , 2017, 140, 1134-1146.	2.3	55
11	Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests). <i>Journal of Clinical Microbiology</i> , 2016, 54, 2337-2342.	1.8	48
12	HPV testing in the context of post-treatment follow up (test of cure). <i>Journal of Clinical Virology</i> , 2016, 76, S56-S61.	1.6	43
13	FAM19A4/miR124 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study. <i>International Journal of Cancer</i> , 2020, 147, 1215-1221.	2.3	40
14	Urine testing as a surveillance tool to monitor the impact of HPV immunization programs. <i>Journal of Medical Virology</i> , 2011, 83, 1983-1987.	2.5	37
15	Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation. <i>Journal of Clinical Pathology</i> , 2015, 68, 135-140.	1.0	37
16	The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium. <i>Journal of Clinical Virology</i> , 2018, 108, 64-71.	1.6	37
17	Defining Optimal Triage Strategies for hrHPV Screen-Positive Women: An Evaluation of HPV 16/18 Genotyping, Cytology, and p16/Ki-67 Cytoimmunochemistry. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1629-1635.	1.1	36
18	Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival. <i>British Journal of Cancer</i> , 2016, 115, 212-222.	2.9	35

#	ARTICLE	IF	CITATIONS
19	Cobas 4800 HPV detection in the cervical, vaginal and urine samples of women with high-grade CIN before and after treatment. <i>Journal of Clinical Pathology</i> , 2015, 68, 567-570.	1.0	27
20	Intra- and inter-laboratory agreement of the FAM19A4/mir124a2 methylation test: Results from an international study. <i>Journal of Clinical Laboratory Analysis</i> , 2019, 33, e22854.	0.9	26
21	Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact. <i>BMC Infectious Diseases</i> , 2013, 13, 519.	1.3	25
22	Use of HPV testing for cervical screening in vaccinated women – Insights from the SHEVa (Scottish) Tj ETQq0 0 0 regBT /Overlock 10 Tff	2.3	25
23	Effective methylation triage of HPV positive women with abnormal cytology in a middle-income country. <i>International Journal of Cancer</i> , 2021, 148, 1383-1393.	2.3	21
24	The potential of biobanked liquid based cytology samples for cervical cancer screening using Raman spectroscopy. <i>Journal of Biophotonics</i> , 2019, 12, e201800377.	1.1	20
25	Sensitivity of RT-PCR testing of upper respiratory tract samples for SARS-CoV-2 in hospitalised patients: a retrospective cohort study. <i>Wellcome Open Research</i> , 2020, 5, 254.	0.9	20
26	Evidence of disrupted high-risk human papillomavirus DNA in morphologically normal cervixes of older women. <i>Scientific Reports</i> , 2016, 6, 20847.	1.6	19
27	Validation of EUROArray HPV test using the VALGENT framework. <i>Journal of Clinical Virology</i> , 2018, 108, 38-42.	1.6	18
28	Clinical performance of methylation as a biomarker for cervical carcinoma in situ and cancer diagnosis: A worldwide study. <i>International Journal of Cancer</i> , 2022, 150, 290-302.	2.3	18
29	Human Papilloma Virus (HPV) Oral Prevalence in Scotland (HOPSCOTCH): A Feasibility Study in Dental Settings. <i>PLoS ONE</i> , 2016, 11, e0165847.	1.1	18
30	Clinical performance of RNA and DNA based HPV testing in a colposcopy setting: Influence of assay target, cut off and age. <i>Journal of Clinical Virology</i> , 2014, 59, 104-108.	1.6	16
31	Effect of HPV Assay Choice on Perceived Prevalence in a Population-based Sample. <i>Diagnostic Molecular Pathology</i> , 2013, 22, 85-90.	2.1	15
32	Droplet digital PCR quantification suggests that higher viral load correlates with improved survival in HPV-positive oropharyngeal tumours. <i>Journal of Clinical Virology</i> , 2020, 129, 104505.	1.6	15
33	HPV infection and pre-term birth: a data-linkage study using Scottish Health Data. <i>Wellcome Open Research</i> , 2019, 4, 48.	0.9	15
34	HPV testing for primary cervical screening: Laboratory issues and evolving requirements for robust quality assurance. <i>Journal of Clinical Virology</i> , 2016, 76, S22-S28.	1.6	14
35	Formalin fixed paraffin embedded (FFPE) material is amenable to HPV detection by the Xpert® HPV assay. <i>Journal of Clinical Virology</i> , 2016, 77, 55-59.	1.6	13
36	Increased risk of HPV-associated genital cancers in men and women as a consequence of pre-invasive disease. <i>International Journal of Cancer</i> , 2019, 145, 427-434.	2.3	13

#	ARTICLE	IF	CITATIONS
37	Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data. <i>BMJ</i> , The, 0, , e068776.	3.0	13
38	Increased Cycling Cell Numbers and Stem Cell Associated Proteins as Potential Biomarkers for High Grade Human Papillomavirus+ve Pre-Neoplastic Cervical Disease. <i>PLoS ONE</i> , 2014, 9, e115379.	1.1	12
39	Longitudinal measurement of HPV copy number in cell-free DNA is associated with patient outcomes in HPV-positive oropharyngeal cancer. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1224-1234.	0.5	12
40	Accuracy of genotyping for HPV16 and 18 to triage women with low-grade squamous intraepithelial lesions: a pooled analysis of VALGENT studies. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 543-551.	1.5	11
41	Human Papillomavirus Detection by Whole-Genome Next-Generation Sequencing: Importance of Validation and Quality Assurance Procedures. <i>Viruses</i> , 2021, 13, 1323.	1.5	11
42	Copy number gain of 11q13.3 genes associates with pathological stage in hypopharyngeal squamous cell carcinoma. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 185-198.	1.5	10
43	Age-specific outcomes from the first round of HPV screening in unvaccinated women: Observational study from the English cervical screening pilot. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 1278-1288.	1.1	10
44	Comparison of the sensitivities of three commercial assays for detection of the high risk HPV types 16, 18 and 45. <i>Journal of Virological Methods</i> , 2013, 193, 147-150.	1.0	9
45	Clinical validation of full genotyping CLART [®] HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening. <i>BMC Cancer</i> , 2020, 20, 396.	1.1	9
46	Should boys receive the human papillomavirus vaccine? No. <i>BMJ: British Medical Journal</i> , 2009, 339, b4921-b4921.	2.4	9
47	The challenges of defining sample adequacy in an era of HPV based cervical screening. <i>Journal of Clinical Virology</i> , 2021, 137, 104756.	1.6	8
48	Self-sampling as the principal modality for population based cervical screening: Five-year follow-up of the PaVDaG study. <i>International Journal of Cancer</i> , 2022, 150, 1350-1356.	2.3	8
49	Ensuring quality in cervical screening programmes based on molecular human papillomavirus testing. <i>Cytopathology</i> , 2019, 30, 273-280.	0.4	6
50	Host chemokine signature as a biomarker for the detection of pre-cancerous cervical lesions. <i>Oncotarget</i> , 2018, 9, 18548-18558.	0.8	6
51	Direct bisulphite conversion of cervical samples for DNA methylation analysis. <i>Epigenetics</i> , 2022, 17, 1173-1179.	1.3	6
52	Development and Validation of a Raman Spectroscopic Classification Model for Cervical Intraepithelial Neoplasia (CIN). <i>Cancers</i> , 2022, 14, 1836.	1.7	6
53	Human papillomavirus testing: the challenges of picking the right tools for the job. <i>Expert Review of Obstetrics and Gynecology</i> , 2011, 6, 643-653.	0.4	5
54	Human Papillomavirus Research: Where Should We Place Our Bets?. <i>Acta Cytologica</i> , 2019, 63, 85-96.	0.7	5

#	ARTICLE	IF	CITATIONS
55	Development of an in-house ELISA to detect anti-HPV16-L1 antibodies in serum and dried blood spots. <i>Journal of Virological Methods</i> , 2019, 264, 55-60.	1.0	4
56	Baseline HPV prevalence in rectal swabs from men attending a sexual health clinic in Scotland: assessing the potential impact of a selective HPV vaccination programme for men who have sex with men. <i>Sexually Transmitted Infections</i> , 2020, 96, 55-57.	0.8	4
57	Impact of the COVID-19 pandemic on human papillomavirus-based testing services to support cervical cancer screening. <i>Acta Dermatovenerologica Alpina, Panonica Et Adriatica</i> , 2021, 30, 21-26.	0.1	4
58	Clinical Performance of Triage Strategies for Hr-HPVâ€“Positive Women; A Longitudinal Evaluation of Cytology, p16/K-67 Dual Stain Cytology, and HPV16/18 Genotyping. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1492-1498.	1.1	4
59	<i><i>FAM19A4/miR124-2</i></i> Methylation Testing and Human Papillomavirus (HPV) 16/18 Genotyping in HPV-Positive Women Under the Age of 30 Years. <i>Clinical Infectious Diseases</i> , 2023, 76, e827-e834.	2.9	4
60	Risk stratification of cervical disease using detection of human papillomavirus (HPV) E4 protein and cellular MCM protein in clinical liquid based cytology samples. <i>Journal of Clinical Virology</i> , 2018, 108, 19-25.	1.6	3
61	Squamous cell carcinoma in the anophthalmic socket:Âa series of four cases with HPV-16 profiling. <i>British Journal of Ophthalmology</i> , 2019, 103, 680-685.	2.1	3
62	Agreement between L1 and E6/E7-based assays for detection of high-risk HPV in cervical, oropharyngeal and penile cancers. <i>Journal of Clinical Pathology</i> , 2023, 76, 467-473.	1.0	3
63	An evaluation of the Qiagen HPV sign for the detection and genotyping of cervical lesions and oropharyngeal squamous cell carcinomas. <i>Journal of Virological Methods</i> , 2014, 207, 128-132.	1.0	2
64	Evaluation of HarmoniaHPV test for detection of clinically significant Human Papillomavirus infection using the VALGENT framework. <i>Journal of Virological Methods</i> , 2021, 294, 114161.	1.0	2
65	Clinical sensitivity of HPV assays for the detection of high grade cervical disease in cervical samples treated with glacial acetic acid. <i>Journal of Clinical Virology</i> , 2016, 79, 32-35.	1.6	1
66	Factors That Influence Confirmation of Neisseria gonorrhoeae Positivity by Molecular Methods. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	1
67	Implication of human papillomavirus (HPV) infection in the paediatric population. <i>BMJ Sexual and Reproductive Health</i> , 2020, 46, 79-81.	0.9	0
68	Risk adaptive triage in cervical screening: challenges and opportunities. <i>Cytopathology</i> , 2021, 32, 712-713.	0.4	0
69	Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection: assessment using the VALGENT framework. <i>Journal of Clinical Pathology</i> , 2023, 76, 172-176.	1.0	0
70	Clinical performance of DNA and RNA based HPV tests for Test of Cure (TOC) post treatment for cervical intraepithelial neoplasia (CIN) - a retrospective study.. <i>Journal of Clinical Virology</i> , 2022, 150-151, 105165.	1.6	0